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The powerful proteomic technique of Tandem Mass Tag labelling with Orbitrap mass spec-
trometry was applied to the quantiﬁcation of relative levels of proteins in serial plasma
samples from 15 women prior to and during labour. Quantitative data were obtained for
1038 proteins, with 217 quantiﬁed in ≥10 sample pairs. Most proteins were unaffected by
labour, 32 had lower levels in labour, and two were increased in labour, and the t test had
sufﬁcient power to determine a signiﬁcant difference in expression in 14 proteins. ELISA
conﬁrmed the signiﬁcant increase of acute phase response components C-reactive protein
and serum amyloid A.
Signiﬁcance: Proteomic technology is constantly advancing, and the latest techniques enable
gel-free analysis of minimally preprocessed, complex biological samples, enabling simul-
taneous identiﬁcation and quantiﬁcation of many hundreds of proteins. The technique ofProteome TMT labelling andOrbitrapmass spectrometry is applicable to the analysis of serialmaternal
plasma samples in order to identify potential markers of the onset of labour.
© 2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY-NC-ND license
through growth of the fetus and uterus to uterine activa-1. Introduction
Human pregnancy has a nominal duration of 40 weeks, at
the end of which a coordinated process of uterine con-
nective tissue remodelling and smooth muscle activation
should result in labour and the vaginal delivery of the fetus.
Spontaneous labour occurring prior to 37 weeks of preg-
nancy (preterm), when fetal development is incomplete, is
associated with perinatal mortality and morbidity, while con-
tinuation of pregnancy post-term is associated with risks and
∗ Corresponding author at: School of Clinical Sciences, University of Br
UK. Tel.: +44 1173313106; fax: +44 1173313035.
E-mail address: robert j phillips@hotmail.com (R.J. Phillips).
http://dx.doi.org/10.1016/j.euprot.2014.09.001
2212-9685/© 2014 The Authors. Published by Elsevier B.V. on behalf of
article under the CC BY-NC-ND license (http://creativecommons.org/lic(http://creativecommons.org/licenses/by-nc-nd/3.0/).
maternal requests at 42 weeks to artiﬁcially induce labour.
Even when labour is underway, problems with fetal position-
ing, maternal blood loss, fetal distress and failure of the labour
to progress can require delivery by emergency Caesarean sec-
tion.
It is presumed that speciﬁc biomarkers will be associated
with changes in each stage of pregnancy, from conceptionistol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY,
tion and labour. Unfortunately, only limited progress has
been made in identifying such markers in amniotic ﬂuid
(AF), cervico-vaginal ﬂuid (CVF), and maternal serum and
European Proteomics Association (EuPA). This is an open access
enses/by-nc-nd/3.0/).
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lasma. Although factors such as chorionic gonadotropin and
orticotropin-releasing hormone are known to increase in
aternal circulation in pregnancy, there are currently no reli-
ble biochemical measures for the onset of preterm labour
n humans [1], with prediction largely relying on known risk
actors (previous preterm delivery, smoking, stress, low BMI)
nd the observation of early symptoms of the onset of labour.
rediction may be improved by combining biochemical and
linical indicators such as cervical length, fetal ﬁbronectin
evels in CVF and maternal serum levels of -fetoprotein,
ranulocyte-colony stimulating factor and defensins or alka-
ine phosphatase [2]. Inﬂammation associated with bacterial
nfection may be linked to the onset of labour in a subset
f women, but this association is confounded by the occur-
ence of infection with no associated inﬂammation [3], and of
nﬂammation in the absence of infection [4], andby the limited
ffectiveness of antibiotics and anti-inﬂammatorymedication
n the prevention of labour.
Historically, the search for biomarkers has focused on
nvestigations of one or more targets selected on the basis
f known physiological roles, molecular interactions or
irect observations of speciﬁc localisation and/or expression
hanges. The development of powerful “omics” technologies
s now fundamentally changing the nature of these investi-
ations. Following the elaboration of a research hypothesis
nd selection of appropriate test samples, it is possible to
creen for the presence and/or alteration of large numbers
f biomolecules such as mRNAs, proteins or metabolites. In
roteomics, liquid chromatography with tandem mass spec-
rometry (LC–MS/MS) has enabled identiﬁcation of proteins
n unlabelled samples, while Difference Gel Electrophoresis
DiGE) enabled protein identiﬁcation and relative quantiﬁca-
ion in two samples by differential ﬂuorescent-tag labelling,
eparation by two-dimensional gel electrophoresis, visualisa-
ion, spot-picking and MS. These approaches have led to the
dentiﬁcation of proteins differentially expressed in AF, CVF
nd maternal serum [5–8].
Labelling of samples with isobaric (equal mass) tags, ﬁrst
emonstrated in 2003 [9], ensures that differentially labelled
eptides comigrate in all processing and chromatographic
eparations. Quantiﬁcation is achieved through collision-
nduced-dissociation in MS/MS, which releases the mass
eporter regions of the mass tags. Each mass tag has a
nique, identiﬁable isotopic label in the mass reporter region.
oth the ‘Isobaric Tag for Relative and Absolute Quantitation’
iTRAQ) and ‘Tandem Mass Tag’ (TMT) isobaric mass tagging
pproaches offer quantiﬁcation without the need for gel elec-
rophoresis. Instead, two ormore protein samples are digested
o peptides, differentially labelled and directly analysed byMS.
hese techniques enable identiﬁcation and quantiﬁcation of
undreds of proteins (from counts of thousands of peptides)
er sample.
Maternal peripheral blood plasma is a readily accessi-
le source of biomarkers that could potentially be used to
etermine the proximity of the onset of labour, susceptibil-
ty to induction of labour and the presence of pathological
omplications of pregnancy. The purpose of this research
as to establish a proof of concept that the TMT pro-
eomics method is capable of detecting changes in maternal
lasma proteins during human labour. We have applied the5 ( 2 0 1 4 ) 10–20 11
relative quantiﬁcation proteomic methodology of TMT MS/MS
to comparison of serial samples of maternal plasma taken
prior to and during active labour, to explore changes in
the plasma proteome associated with the process of labour.
We identiﬁed a number of differentially regulated pro-
teins, and used absolute quantiﬁcation by ELISA on an
independent set of samples to attempt to validate the
MS quantiﬁcation of three selected proteins, and to com-
pare the expression in similar serial plasma samples from
women delivering in the absence of labour. As expected,
most maternal proteins remained stable, but the TMT MS
methods detected changes with labour in more than 30
proteins, although the study only had sufﬁcient power to
determine statistical signiﬁcance in differential expression
of 14 proteins, owing to the limited number of samples
used for MS analysis. Strong correlation between the MS
and ELISA results for two of the proteins suggests that
TMT MS can be used to accurately determine changes in
expression of potential biomarkers. However, the poor cor-
relation seen with the third protein highlights the need
for independent validation of biomarkers identiﬁed by
MS.
2. Materials and methods
2.1. Plasma samples
This study had the approval of the National Research Ethics
Service (NRES Committee South West – Central Bristol) and
all women gave informed written consent. Venous blood was
taken from 15 women who went into spontaneous labour
(SL) and had vaginal deliveries, 13 women whose labour was
induced (IOL; 10 with vaginal deliveries, three with emer-
gency Caesarean sections) and 13 women who did not go into
labour prior to delivery (NL; eight with elective C-sections,
twowith emergency C-sections). Medians of clinical attributes
in these groups were: maternal age, SL 31, IOL 32, NL 32;
gestational age, SL 41, IOL 41, NL 38; parity, SL 1.0, IOL 0.0,
NL 1.5; birth weight (kg), SL 3.7, IOL 3.7, NL 3.5; male to
female offspring; SL 5:10, IOL 6:7, NL 5:5; duration of labour
(h:mm), SL 5:00, IOL 5:23. Two blood samples were obtained
from each woman; the ﬁrst at the initial clinical assessment,
when there were no signs of labour and the second dur-
ing established labour or at C-section. Proteomic analysis
was conducted on a subset of 11 SL and four IOL sam-
ple pairs, with clinical details given in Table 1. All women
delivered in St Michael’s Hospital, Bristol, UK, and were of
good general health with singleton pregnancies without com-
plications such as antepartum haemorrhage, hypertension,
pre-eclampsia or diabetes.
Blood was aspirated into K2EDTA vacutainers (Becton
Dickinson, Oxford, UK) and transferred into tubes contain-
ing protease inhibitors (leupeptin hydrochloride (1g/ml),
aprotinin (1g/ml) and pepstatin A (1g/ml); Sigma–Aldrich,
Gillingham, UK) and mixed well. Plasma was separated
from cells by centrifugation at 2000× g for 10min at room
temperature. Clear plasma was then spun at 12,000× g for
5min. Supernatant was divided into aliquots and stored at
−80 ◦C.
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2.2. Proteomic analysis
2.2.1. TMT labelling and cation exchange chromatography
Aliquots of 100g of two or six plasma samples per experi-
ment were digested with trypsin and labelled with Tandem
Mass Tag (TMT) duplex or sixplex reagents according to the
manufacturer’s protocol (Thermo Fisher Scientiﬁc, Loughbor-
ough, UK). Sixplex labelling produced comparable results to
duplex labelling, with reduced expense owing to analysis of
three sample pairs per MS run. In brief, 100g of each sam-
ple was resuspended in 50mM TEAB containing 10mM TCEP
and incubated at 55 ◦C for 1h. The samples were cooled and
iodoacetamide was then added to a ﬁnal concentration of
17mM and the samples incubated for a further 30min at room
temperature protected from light. The reduced and alkylated
proteins were then precipitated overnight using six volumes
of pre-chilled acetone (−20 ◦C) and then spun at 8000× g for
10min at 4 ◦C to pellet the precipitated material. Following
removal of the acetone, the protein pellets were resuspended
in 100mM TEAB containing 2.5g sequencing grade trypsin
(Promega) and digested overnight at 37 ◦C. Each of the six TMT
reagents (0.8mg) were resuspended in anhydrous acetonitrile
and added to one of the six plasma samples. The labelling
reaction was allowed to proceed for 1h at room temperature
and then quenched by the addition of 0.25% hydroxylamine
(ﬁnal concentration) and incubation for a further 15min. After
labelling, samples were combined in equal amounts, and a
50g aliquot of this pooled sample evaporated to dryness
and resuspended in buffer A (10mM KH2PO4, 25% MeCN,
pH3) prior to fractionation by strong cation exchange using
an Ettan LC system (GE Healthcare, Little Chalfont, UK). The
sample was loaded onto a polysulphoethyl A column (100mm
long×2.1mm internal diameter, 5m particle size, 200 A˚ pore
size; PolyLC Inc, Columbia, MD, USA) in buffer A and peptides
eluted with an increasing gradient of buffer B (10mM KH2PO4,
25%MeCN, 1M KCl, pH3) from 0 to 100% over 30min. Five
fractions were collected, evaporated to dryness, resuspended
in 5% (v/v) formic acid and desalted using SepPak cartridges
according to the manufacturer’s instructions (Waters, Milford,
MA, USA). Eluate from the SepPak cartridge was evaporated to
dryness and resuspended in 1% (v/v) formic acid.
2.2.2. Nano-LC mass spectrometry
Cation exchange fractions were further fractionated using a
Dionex UltiMate 3000 Nano LC system in line with an LTQ-
Orbitrap Velos mass spectrometer (Thermo Fisher Scientiﬁc).
Peptides in 1% (v/v) formic acid were injected onto an Acclaim
PepMap C18 Nano-Trap column (Dionex, Thermo Fisher Sci-
entiﬁc). After washing with 0.5% (v/v) acetonitrile, 0.1% (v/v)
formic acid, peptides were resolved on a 250mm×75m
AcclaimPepMapC18 reverse phase analytical column (Dionex)
over a 150min organic gradient, using seven gradient seg-
ments of different dilutions of 80% (v/v) acetonitrile, 0.1% (v/v)
formic acid (1–6% over 1min, 6–15% over 58min, 15–32% over
58min, 32–40% over 3min, 40–90% over 1min, held at 90% for
6min and then reduced to 1% over 1min) with a ﬂow rate of
300nl/min. Peptideswere ionised bynano-electrospray ionisa-
tion at 2.0 kV using a stainless steel emitter with an internal
diameter of 30m (Thermo Fisher Scientiﬁc) and a capillary
temperature of 250 ◦C. Tandem mass spectra were acquired
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sing an LTQ-Orbitrap Velos mass spectrometer controlled by
calibur 2.1 software and operated in data-dependent acqui-
ition mode. The Orbitrap was set to analyse the survey scans
t 60,000 resolution (at m/z 400) in the mass range m/z 300 to
800 and the top ten multiply charged ions in each duty cycle
elected for MS/MS fragmentation using higher-energy col-
isional dissociation (HCD) with normalised collision energy
f 45%, activation time of 0.1ms and at a resolution of
500 within the Orbitrap. Charge state ﬁltering, where unas-
igned precursor ions were not selected for fragmentation,
nd dynamic exclusion (repeat count 1; repeat duration 30 s;
xclusion list size 500) were used.
.2.3. Data analysis
he raw data ﬁles were processed and quantiﬁed using Pro-
eome Discoverer software v1.2 (Thermo Fisher Scientiﬁc)
nd searched against the UniProt/SwissProt Human database
elease version 57.3 (20,326 entries) using the SEQUEST (Ver. 28
ev. 13) algorithm. Peptide precursormass tolerancewas set at
0ppm, and MS/MS tolerance was set at 0.8Da Search criteria
ncludedoxidationofmethionine (+15.9949) as a variablemod-
ﬁcation and carbamidomethylation of cysteine (+57.0214) and
he addition of the TMT duplex (+225.156) or sixplex (+229.163)
ass tags to peptide N-termini and lysine as ﬁxed modiﬁ-
ations. Searches were performed with full tryptic digestion
nd a maximum of one missed cleavage was allowed. The
everse database search option was enabled and all peptide
ata was ﬁltered to satisfy a peptide false discovery rate (FDR)
f 5%. The Proteome Discoverer software generates a reverse
decoy” database from the same protein database and any
eptides passing the initial ﬁltering parameters that were
erived from this decoy database are deﬁned as false positive
dentiﬁcations. The minimum cross-correlation factor (Xcorr)
lter was readjusted for each individual charge state sepa-
ately to optimally meet the predetermined target FDR of 5%
ased on the number of random false positive matches from
he reverse decoy database. Thus each data set has its own
assing parameters. Quantiﬁcation used a peak integration
indow tolerance of 0.0075Dawith the integrationmethod set
s the most conﬁdent centroid. The data analysis parameters
nsured that only quantitative data for peptides unambigu-
usly assigned to a single protein were included. The data
ere not ﬁltered to remove single peptide hits, so proteins
ere quantiﬁed on the basis of one or more unique peptides.
or each plasma sample pair, the ratios of in-labour:pre-labour
rotein levelswere calculated frommedians of quantiﬁedpep-
ide ratios.
The compatibility of peptide labelling using duplex and six-
lex TMT was assessed by t test comparing ratios of protein
evels determined with each type of label, which showed no
igniﬁcant differences between the labels for any protein (data
ot shown).
.3. ELISA
hree proteins (CRP, SAA and APOA4) that were identiﬁed by
roteomic analysis as being present at signiﬁcantly differ-
nt levels in pre-labour and in-labour samples were further
nalysed by quantitative ELISA. Total plasma protein concen-
ration was determined for each sample by the BCA assay5 ( 2 0 1 4 ) 10–20 13
(Thermo Fisher Scientiﬁc), and was adjusted to 10mg/ml.
Further 1:40 sample dilutions were required to bring the
samples within the linear ranges of the assays. ELISAs were
performed according to manufacturers’ instructions. Plasma
samples were diluted as described above, and protein stan-
dards of known concentration were diluted serially seven
times. Diluted samples, standards and protein-free blanks
were pipetted into a 96-well plate pre-coated with capture
antibody and incubated at room temperature to allow forma-
tion of antibody–antigen complexes. Unbound antigen was
removed with ﬁve plate washes and then HRP-conjugated
detection antibody was added and incubated at room tem-
perature to allow formation of antibody–antigen–antibody
complexes. Excess detection antibody was washed off, chro-
mogenic TMB substrate was added and after 15min colour
development was stopped by addition of H2SO4. Absorbance
at 450nm was measured, and antigen concentration in each
well determined by comparison of absorbance with the stan-
dard curve of knowndilutions, correcting for the initial sample
dilution. ELISA tests used were CRP (E-80CRP, ICL Inc., Port-
land, OR, USA), SAA (KHA0011, Life Technologies) and APOA4
(E91967Hu-USC, USCN Life Science, Houston, TX, USA).
3. Results
3.1. Changes in the plasma proteome with labour
Proteomic analysis was used to determine the ratios of
in-labour:pre-labour protein levels in 15 women, with the
number of proteins quantiﬁed in each sample pair shown in
Table 1. This analysis provided quantitative data on a total
of 1038 proteins, with 421 only counted in a single pair, 400
counted in two to nine of the 15 pairs, 66 counted in 10
to 14 pairs, and 151 quantiﬁed in all 15 sample pairs. For
those 217 proteins quantiﬁed in 10 to 15 of the pairs, the
individual in-labour:pre-labour ratios were log2-transformed
prior to statistical analysis of the difference of the means by
one-sample t tests. In these tests, the expected mean value
was zero, corresponding to a null hypothesis that there was
no difference between the pre-labour and in-labour ratios.
A volcano plot (Fig. 1) shows the relationship between the
means of the log-transformed ratios for each protein and
the negative transformation of the log10-transformed t test
p-values (so that lower p-values give a higher value on the
Y-axis). This plot shows that there was a signiﬁcant proba-
bility, according to the t test analysis, that 32 proteins were
present at lower levels in labour and two were increased
(Table 2), while 185 proteins were not signiﬁcantly differ-
ent in the pre-labour and in-labour samples (Table 3). Post
hoc power analysis was performed on the results of the
proteins that appeared to be differentially expressed. Using
the values of sample means, standard deviations, an ˛ (type
I error rate) of 0.05, and the numbers of samples report-
ing a proteomic ratio for each protein, the power for a
two-sided test was calculated with the online calculator at
http://www.stat.ubc.ca/∼rollin/stats/ssize/n1.html. Power is
the probability of a test detecting a differencewhen one exists:
it is determined using the type II error rate, and a power of
≥0.8 is a common target for statistical tests, indicating that
14 e u pa open proteomics 5 ( 2 0 1 4 ) 10–20
Table 2 – Proteins whose levels are changed in MS analysis of serial in-labour plasma relative to pre-labour plasma.
Uniprot HUGO Mean S.D. p Power v.m.d. Protein name
P06727 APOA4 −0.34 0.25 0.00 1.00 0.25 Apolipoprotein A-IV
P02753 RBP4 −0.22 0.20 0.00 0.99 0.15 Retinol-binding protein 4
O75636 FCN3 −0.22 0.21 0.00 0.99 0.16 Ficolin-3
Q6PCB0 VWA1 −0.17 0.17 0.00 0.96 0.14 von Willebrand factor A domain-containing protein 1
O00391 QSOX1 −0.20 0.20 0.00 0.96 0.16 Sulfhydryl oxidase 1
P02749 APOH −0.11 0.13 0.01 0.90 0.10 Beta-2-glycoprotein 1
P02741 CRP 0.93 1.05 0.01 0.89 0.85 C-reactive protein
P02765 AHSG −0.13 0.16 0.01 0.86 0.12 Alpha-2-HS-glycoprotein
P04070 PROC −0.16 0.20 0.01 0.86 0.15 Vitamin K-dependent protein C
P01243 CSH1 −0.16 0.17 0.01 0.88 0.15 Chorionic somatomammotropin hormone
P51884 LUM −0.12 0.16 0.01 0.82 0.12 Lumican
P17936 IGFBP3 −0.15 0.21 0.01 0.82 0.16 Insulin-like growth factor-binding protein 3
P02735 SAA2 1.11 1.52 0.01 0.80 1.10 Serum amyloid A protein
Q8N5G2 TMEM57 −0.15 0.16 0.02 0.85 0.15 Macoilin
P02656 APOC3 −0.20 0.28 0.02 0.77 0.21 Apolipoprotein C-III
O43184 ADAM12 −0.11 0.14 0.02 0.78 0.11 Disintegrin, metalloproteinase domain-containing protein 12
Q01459 CTBS −0.16 0.22 0.02 0.74 0.18 Di-N-acetylchitobiase
Q15582 TGFBI −0.14 0.17 0.03 0.75 0.16 Transforming growth factor-beta-induced protein ig-h3
P10909 CLU −0.12 0.20 0.03 0.69 0.15 Clusterin
P00740 F9 −0.09 0.13 0.03 0.68 0.10 Coagulation factor IX
P01019 AGT −0.11 0.18 0.03 0.65 0.14 Angiotensinogen
P19823 ITIH2 −0.12 0.19 0.03 0.66 0.14 Inter-alpha-trypsin inhibitor heavy chain H2
P23142 FBLN1 −0.11 0.18 0.03 0.65 0.14 Fibulin-1
P29622 SERPINA4 −0.17 0.28 0.03 0.65 0.21 Kallistatin
P07477 PRSS1 −0.12 0.16 0.03 0.69 0.14 Trypsin-1
Q96PD5 PGLYRP2 −0.17 0.29 0.04 0.64 0.21 N-acetylmuramoyl-l-alanine amidase
Q96IY4 CPB2 −0.10 0.17 0.04 0.63 0.13 Carboxypeptidase B2
P00747 PLG −0.12 0.21 0.04 0.63 0.16 Plasminogen
P49908 SEPP1 −0.17 0.26 0.04 0.63 0.21 Selenoprotein P
Q9UIQ6 LNPEP −0.11 0.15 0.04 0.64 0.13 Leucyl-cystinyl aminopeptidase
Q9UGM5 FETUB −0.20 0.35 0.05 0.59 0.26 Fetuin-B
Q9UHG3 PCYOX1 −0.19 0.27 0.05 0.61 0.24 Prenylcysteine oxidase 1
Q5SYB0 FRMPD1 −0.11 0.19 0.05 0.59 0.14 FERM and PDZ domain-containing protein 1
Q92954 PRG4 −0.10 0.19 0.05 0.58 0.14 Proteoglycan 4
Statistical signiﬁcance was determined by t test. The power of the t test to determine signiﬁcance, and the mean difference that can conﬁdently
lead to a declaration of signiﬁcance, were calculated for each protein. The t test was only sufﬁciently powered to determine signiﬁcance for
the top 14 proteins in the table. Abbreviations: HUGO, approved symbol from the HUGO Gene Nomenclature Committee database; Mean, mean
of log2[in-labour/pre-labour] ratios (positive values (bold) indicate increase in-labour, negative values indicate decrease with labour); MS, mass
labou
alid mspectrometry; p, p values of one-sample t tests of log2[in-labour/pre-
labour] ratios; Uniprot, Uniprot database accession number; v.m.d., v
a test has an 80% probability of detecting a difference when
one exists. A related measure is the valid mean difference,
and it was calculated using the numbers of samples reporting
a proteomic ratio, the standard deviation and the test mean
(0), with an ˛ of 0.05 and power of 0.80, with the online cal-
culator at http://www.biomath.info/power/ttest1gp.htm. The
valid mean difference is the minimum difference from the
test mean that can be conﬁdently reported as signiﬁcant, for
a given power. Both of these test statistics are reported in
Table 3.
3.1.1. Quantiﬁcation of selected proteins by ELISA
The TMT proteomic analysis provides relative quantiﬁcation
of levels of a large number of proteins in samples com-
pared directly with each other. ELISA was used to investigate
the relationship between this relative quantiﬁcation and the
absolute protein concentrations. The three proteins chosen
for ELISA analysis were C-reactive protein (CRP) and serum
amyloid A (SAA), which were the proteins with the high-
est fold-change in expression according to the MS analysis,r] ratios, test value=0; S.D., standard deviation of log2[in-labour/pre-
ean difference, calculated with a power of 0.80.
and apolipoprotein A4 (APOA4), the protein associated with
the lowest p-value for comparison of pre-labour and in-
labour expression, which we had previously identiﬁed as
being differentially expressed in in-labour compared with
not-in-labour plasma samples [10]. We measured the levels
of these three proteins by ELISA in the 15 plasma sample
pairs included in the MS analysis. The Pearson product-
moment correlation coefﬁcients (r) and associated p-values
for the correlation between the ratios of pre-labour and in-
labour samples by MS and ELISA were: CRP, r=0.99, p<0.001;
SAA, r=0.636, p=0.008; APOA4, r=0.134, p=0.620, suggesting
good correlation between the methods for CRP and SAA, but
poor correlation for APOA4. Coefﬁcients of variance (standard
deviation/mean) for each method were calculated using the
nontransformed ratios and were: CRP, MS=1.06, ELISA=1.03;
SAA, MS=1.36, ELISA=1.92; APOA4, MS=0.19, ELISA=0.09.We also measured the expression of these proteins in fur-
ther paired, serial plasma samples from four spontaneous
(SL) and nine induced (IOL) deliveries, and in serial samples
from 13 deliveries by caesarean section in the absence of
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Table 3 – Plasma proteins not signiﬁcantly affected by labour.
Uniprot Mean S.D. Uniprot Mean S.D. Uniprot Mean S.D. Uniprot Mean S.D.
A6NJ16 −0.079 0.216 P01833 −0.068 0.171 P04278 −0.148 0.361 P35858 −0.094 0.217
O14791 −0.049 0.200 P01834 0.001 0.282 P04433 −0.026 0.172 P35908 −0.373 1.349
O43423 0.134 0.547 P01842 −0.044 0.178 P05090 −0.109 0.324 P36955 −0.087 0.183
O43866 −0.027 0.260 P01857 0.004 0.264 P05155 0.051 0.282 P36980 0.019 0.227
O75443 −0.072 0.234 P01859 −0.025 0.202 P05156 −0.064 0.231 P43251 −0.026 0.413
O75533 −0.030 0.227 P01860 −0.086 0.242 P05160 −0.073 0.213 P43652 −0.071 0.200
O75882 −0.062 0.236 P01861 −0.146 0.557 P05452 −0.106 0.216 P48730 −0.001 0.253
O95445 −0.099 0.265 P01871 −0.003 0.235 P05543 −0.004 0.178 P48740 −0.141 0.245
P00450 −0.047 0.243 P01876 −0.093 0.270 P05546 −0.076 0.178 P51811 −0.029 0.225
P00734 −0.046 0.185 P01877 −0.001 0.223 P06310 0.271 0.902 P52848 −0.156 0.378
P00736 −0.047 0.189 P01880 0.046 0.426 P06396 −0.088 0.218 P54108 −0.091 0.228
P00738 0.075 0.302 P02042 0.071 0.278 P06681 −0.090 0.287 P55056 −0.038 0.292
P00739 −0.018 0.199 P02647 −0.095 0.206 P06702 −0.103 1.961 P55058 −0.051 0.274
P00740 −0.085 0.135 P02649 −0.154 0.318 P07225 −0.062 0.191 P59665 0.044 0.657
P00742 −0.084 0.210 P02652 −0.136 0.306 P07357 −0.034 0.234 P60709 −0.200 0.748
P00748 −0.129 0.243 P02654 −0.063 0.310 P07358 −0.053 0.174 P61626 0.092 0.311
P00751 0.007 0.228 P02655 −0.110 0.204 P07360 −0.027 0.177 P68871 0.111 0.315
P00915 0.072 0.320 P02671 −0.058 0.244 P08185 −0.153 0.282 P69905 0.103 0.339
P01008 −0.067 0.196 P02675 −0.052 0.241 P08519 −0.267 0.832 P78563 0.010 0.196
P01009 −0.025 0.217 P02679 −0.049 0.247 P08571 0.051 0.366 P80108 −0.080 0.167
P01011 0.081 0.258 P02743 −0.044 0.213 P08603 −0.056 0.200 P80748 −0.080 0.188
P01019 −0.112 0.181 P02745 −0.056 0.224 P08697 −0.035 0.308 Q00887 −0.234 0.418
P01023 −0.038 0.234 P02746 −0.055 0.198 P09871 −0.071 0.190 Q00888 −0.028 0.318
P01024 −0.051 0.194 P02747 −0.045 0.173 P0C0L4 0.086 0.274 Q03591 0.013 0.392
P01031 −0.014 0.231 P02748 0.048 0.226 P10643 −0.080 0.240 Q06033 −0.040 0.214
P01034 −0.014 0.183 P02750 0.137 0.285 P12259 −0.059 0.178 Q08380 −0.027 0.273
P01042 −0.091 0.203 P02751 −0.265 0.573 P13645 −0.149 1.222 Q13046 −0.165 1.185
P01591 −0.071 0.153 P02760 −0.077 0.234 P13671 −0.061 0.220 Q13219 −0.116 0.415
P01598 −0.016 0.184 P02763 0.050 0.255 P13727 −0.106 0.494 Q14520 −0.047 0.312
P01608 −0.032 0.244 P02766 −0.026 0.271 P14151 −0.020 0.189 Q14624 −0.038 0.177
P01609 −0.068 0.270 P02768 −0.044 0.208 P15169 −0.056 0.207 Q14964 −0.077 0.158
P01611 −0.054 0.217 P02774 −0.094 0.241 P18428 0.283 0.558 Q16610 −0.043 0.290
P01613 0.039 0.196 P02775 0.169 0.821 P19652 −0.012 0.216 Q4LDE5 −0.114 0.173
P01625 0.016 0.233 P02787 −0.060 0.205 P19827 −0.074 0.198 Q58FF6 0.129 0.371
P01700 −0.052 0.173 P02790 −0.051 0.192 P20742 −0.250 0.893 Q5T619 0.142 0.325
P01702 −0.053 0.465 P03952 −0.085 0.203 P20851 −0.040 0.175 Q6NUM9 −0.104 0.196
P01714 −0.041 0.256 P04003 −0.049 0.275 P22352 −0.082 0.262 Q7RTZ1 −0.010 0.116
P01715 −0.015 0.181 P04004 −0.062 0.206 P22792 −0.034 0.223 Q8TAQ9 −0.056 0.283
P01717 −0.088 0.197 P04114 −0.096 0.207 P22891 −0.053 0.222 Q96KN2 −0.108 0.258
P01743 0.008 0.361 P04180 −0.045 0.229 P23083 −0.080 0.310 Q9NZP8 −0.060 0.188
P01764 −0.058 0.160 P04196 −0.094 0.173 P25311 −0.084 0.351 Q9UK55 0.010 0.285
P01766 0.013 0.186 P04208 −0.042 0.183 P27169 −0.060 0.219 Q9UKX3 −0.024 0.204
P01767 −0.044 0.324 P04211 −0.082 0.217 P27918 −0.038 0.162 Q9UNH7 −0.095 0.257
P01773 −0.122 0.362 P04217 −0.057 0.217 P32119 0.112 0.277 Q9Y6R7 −0.157 0.299
P01779 −0.035 0.209 P04220 −0.038 0.246 P33151 −0.136 0.231
P01780 −0.032 0.255 P04264 −0.282 1.019 P35527 −0.562 1.212
P01781 −0.058 0.266 P04275 0.027 0.547 P35542 0.076 0.299
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database accession number.
abour (NL). Fig. 2A shows the spread of the log-transformed
atios of protein concentrations in the combined in-labour
IL =SL+ IOL) groups, compared with NL. Fig. 2B shows the
elationships of the samples in each of the serial pairs.
To compare the levels of protein in the paired serial sam-
les determined by ELISA, differences between the paired
amples were assessed using the nonparametric Wilcoxon
igned-rank test, with a null hypothesis that the medians of
he groups of paired sampleswere identical. For the IL samples
easured by both MS and ELISA, results of the Wilcoxon
est were: CRP, z=−2.783, p=0.005; SAA, z=−3.294, p=0.001;
POA4, z=−1.136, p=0.254. For the IL samples measuredard deviation of log2[in-labour/pre-labour] ratios; Uniprot, Uniprot
only by ELISA, the results were: CRP, z=−1.782, p=0.075;
SAA, z=−2.271, p=0.023; APOA4, z=−0.078, p=0.936. For the
NL samples, the results were: CRP, z=−0.734, p=0.465; SAA,
z=−0.357, p=0.719; APOA4, z=−1.070, p=0.285. These results
demonstrate higher levels of expression in labour for CRP and
SAA. The changes in these proteins were similar in the SL and
IOL groups.4. Discussion
To the best of our knowledge, this study is the ﬁrst to
use TMT labelling and Orbitrap Velos mass spectrometry to
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Fig. 1 – Volcano plot comparing protein levels in paired
pre-labour and in-labour samples. The X-axis displays a
measure of fold-change of expression, with higher levels
in-labour shown to the right, and higher levels pre-labour
to the left of zero. The Y-axis indicates the probability that
the observed changes in protein level did not occur by
chance alone; statistically signiﬁcant changes according to t
test are shown with open circles, and three open circles
We have detected proteins not previously associated withcorresponding to proteins measured by ELISA are labelled.
describe proteomic changes in maternal plasma associated
with human parturition. The results demonstrate the value
of this approach to identify proteins relevant to spontaneous
and induced labour. This technique enabled measurement of
a broad spectrum of plasma proteins in serial samples from
the same women before and during labour, without the addi-
tional sample-processing step of depletion of high-abundance
proteins. We have previously demonstrated changes in mater-
nal plasma proteins with labour in a cross-sectional study
[10]: however, the results were limited to low-abundance
proteins (after removal of the 20 most abundant proteins
such as albumin, IgG, and transferrin, by immunodeple-
tion) and to proteins that could be visualised after 2D-DIGE.
Although immunodepletion is a useful step in MS workﬂows
for enriching low-abundance proteins, it results in an artiﬁcial
modiﬁcation of the protein proﬁle. Low-abundance proteins,
such as apolipoproteins, can bind to high-abundance albumin
and so can be affected by depletion. We therefore exploited
the ability of the Orbitrap TMT MS approach to quantify
low-abundance proteins without immunodepletion to obtain
an unmodiﬁed proﬁle of the plasma proteome. This is an
important advantage, although it is possible that some low-
abundance proteins were not identiﬁed by our approach.
It is notoriously difﬁcult to predict the onset of labour, so
we focused our study on women attending the post-term,
pre-induction Day Assessment Unit at St Michael’s Hospital,
who we were able to monitor relatively closely. This study
presents a quantitative record of the maternal plasma pro-
teome in late pregnancy. These proteins are associated with
many different physiological pathways, such as plasminogen
activation, blood coagulation, integrin pathway signalling ands 5 ( 2 0 1 4 ) 10–20
the renin–angiotensin system. A similar range of maternal
plasma proteins has been described in proteomic studies of
potential biomarkers for pre-eclampsia [11]. This functional
complexity is to be expected [12], given the essential home-
ostatic role of plasma, providing metabolic, hormonal and
regulatory links to most maternal organs and to the placenta.
The proteins that we have identiﬁed as being differentially
expressed in-labour compared with pre-labour have multi-
ple functions. For instance, apolipoprotein A-IV is a part of
the protein–lipid transport system and is a major compo-
nent of high-density lipoproteins (HDL) and chylomicrons.
The levels of APOA4 decrease during the last weeks of preg-
nancy and during labour [10]. Retinol-binding protein (RBP4)
transports retinol (vitaminA) in plasma, and is involved in reg-
ulating insulin and glucosehomeostasis in pregnancy.Women
with gestational diabetes tend to have low levels of RBP4 in
the circulation, but previous studies have found no changes
in RBP4 with parturition [13]. Ficolin-3 is part of a family
of pattern recognition molecules of the innate immune sys-
tem. Decreased levels of ﬁcolin-2 and ﬁcolin-3, resulting in
impaired removal of trophoblastmaterial, have beenproposed
as a factor in the pathogenesis of pre-eclampsia [14]. APOH
might have a role in the pathogenesis of antiphospholipid
syndrome in pregnancy [15].
The patterns of protein changes that we detected support
the view that some elements of labour resemble an inﬂam-
matory reaction [10,16]. Analysis of changes in acute phase
proteins during inﬂammatory responses showed that CRP (C-
reactive protein), SAA (serum amyloid A) and haptoglobins
increased, whereas apolipoproteins A-I, A-IV and E, together
with transthyretin, several macroglobulins and glycoproteins,
decreased [17]. A decrease in APOA1 with labour has been
described [18]. CRP and SAA are classical acute-phase proteins
whose plasma concentrations increase in response to diverse
stimuli, including trauma, infection and hypoxia [19]. A major
function of CRP is to bind polysaccharides in pathogens and
phospholipids in damaged cells, thus contributing to innate
immunity. CRP can activate the complement cascade and also
promote phagocytosis and the release of proinﬂammatory
cytokines by monocytes. An association between maternal
stress and preterm birth has been described, and recent evi-
dence shows that antenatal stress and preterm labour are
associated with increased maternal levels of interleukin-6,
TNF- and CRP [20]. The changes in acute phase proteins after
inﬂammatory stimuli are evident within a few hours but can
be maintained over a period of several days or weeks [19].
A study in an African population showed that maternal CRP
levels peak a fewdays postpartum [21]. CRP is elevated in preg-
nancy complications such as pre-eclampsia that may have an
immunological, inﬂammatory pathogenesis [22]. SAA2 is an
apolipoprotein of the HDL complex and may inﬂuence choles-
terol metabolism during inﬂammation. Little is known about
maternal SAA levels in women around parturition, although
SAA levels are known to increase in the newborn in response
to ischaemia and have been used to predict the severity of
hypoxic encephalopathy in affected children [23].labour, but reported as potential biomarkers for pregnancy
complications. AHSG, also known as fetuin-A, might be
involved in the regulation of trophoblast invasion in early
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Fig. 2 – Measurement by ELISA of levels of selected proteins (CRP, SAA, APOA4) in serial plasma samples (S1 and S2) from
women delivering in labour (IL). IL1, sample pairs from 11 spontaneous (SL) and four induced (IOL) deliveries, also
measured by mass spectrometry. IL2, sample pairs from four SL and nine IOL deliveries. NL, sample pairs from 13 deliveries
in the absence of labour (NL). (A) Box and whisker plot shows quartiles of log2-transformed ratios of levels, with outliers
indicated by open circles. Positive values indicate an increase in protein level with labour and/or advancing gestation. (B)
Concentrations of proteins in individual serial plasma sample pairs. Substantially decreasing levels (S1>1.5*S2) are
indicated with green colouring, increasing levels (S2>1.5*S1) with red. Medians of S1 and S2 were compared by Wilcoxon
signed-rank test, identifying signiﬁcant differences for CRP in IL1 (p=0.005), and SAA in IL1 (p=0.001) and IL2 (p=0.023), as
indicated by asterisks. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
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regnancy, and there is controversy as to whether AHSG levels
re elevated [24] or decreased [25] in women who develop pre-
clampsia. We also detected a signiﬁcant decrease in fetuin-B
n women in labour. This protein is a protease inhibitor that
acilitates sperm penetration through the zona pellucida of
he oocyte, but its potential role in parturition is not known.
Some proteins related to the blood coagulation cascade
ere signiﬁcantly decreased in labour, including PROC, F9 and
WA1. The latter interacts with heparan sulphate proteogly-
ans that are essential components of basal membranes and
lay vital roles in vascularisation. It remains to be investi-
ated whether these changes are related to parturition or to
aemostatic changes to help prevent excessive postpartum
leeding.
Several of the proteins detected have enzyme activities
elated to oxidation and reduction reactions. For example,
SOX1 catalyzes the oxidation of sulphydryl groups in pro-
eins and PCYOX1 cleaves thioether bonds in prenylatedproteins. SERPINA4 (kallistatin) and SEPP1 have antioxi-
dant properties. We observed reduced levels in labour of
components of the renin-angiotensin system such as AGT
(angiotensinogen) and LNPEP aminopeptidase, presumably
reﬂecting their involvement in the regulation of maternal
blood pressure and electrolyte homeostasis during the process
of birth.
A cluster of proteins with growth and metabolic functions
includes CSH1 (chorionic somatomammotropic hormone or
‘placental lactogen’), which is only produced during preg-
nancy and is partly responsible for metabolic adaptation to
pregnancy, fetal growth and lactation, and IGFBP3, which is
involved in insulin-like growth factor (IGF)-dependent and
IGF-independent regulation of growth and proliferation [26].
While more evidence is needed to relate these changes to the
mechanism of parturition in women, the ﬁndings recall the
ancient view that fetal demands for energy and growth near
term determine the onset of labour [27].
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The relative abundance of proteins related to the com-
plement pathway, namely CRP, FCN3, CLU, and FBLN1, and
the association between angiotensinogen and complement
C3, and between plasminogen and C1 and C5 suggests a role
for innate immune defence mechanisms at parturition and
early puerperium, a time when the uterine cavity is vulnera-
ble to microbial invasion. Our ﬁndings ﬁt with the proposed
tendency for classical (C1) complement activation during
pregnancy [28]. Notably, some cases of spontaneous preterm
labour are associated with activation of the alternative (C3)
complement pathway [29]. Possible links between clusterin
(CLU) and angiotensinogen (AGT) have been described in
womenwith pre-eclampsia: bothCLUandAGTmodulate tran-
scriptional activity and function of the labour-promotingNFB
pathway [30,31].
Most of the proteins detected did not show signiﬁcant
concentration changes with labour. The stability of these
proteins in the circulation is reassuring and conﬁrms that
parturition is a physiological process that involves changes
in a few selective pathways [32,33]. However, it should be
noted that we do not know, for any of these proteins, what
level of change is biologically signiﬁcant, as opposed to sta-
tistically signiﬁcant. Furthermore, with the limited number
of samples used for MS analysis, the t test for differential
expression was only sufﬁciently powered to conﬁdently deter-
mine signiﬁcance in the 14 proteins with the lowest p values,
reﬂecting smaller standard deviations and/or larger effect
sizes. We therefore attempted to validate the MS results using
ELISA.
Three proteins were selected for further analysis by ELISA,
on the basis of the high fold-change between serial sam-
ples (CRP and SAA) or very low p-value associated with the
change (APOA4), rather than a particular physiological inter-
est compared with other proteins. The increase in acute phase
proteins CRP and SAA with labour that was observed by MS
was conﬁrmed by ELISA, with strong correlation between the
two methods, demonstrating the value of the TMT mass spec-
trometry to identify selective protein changes in complex
plasma mixtures. According to the proteomic analysis, the
change in APOA4 with labour was smaller than the changes
in CRP and SAA, although highly signiﬁcant, but ELISA did not
detect any alteration in APOA4, and the correlation between
MS and ELISA values for APOA4 was poor. This difference
might be due to more accurate measurement of small dif-
ferences in protein levels by one or other of the methods.
It is possible that, perhaps due to the presence of post-
translational modiﬁcations or splice variants, the methods do
not measure the same APOA4 moiety. Although the ELISA was
validated by its manufacturer and contained puriﬁed APOA4
protein for calibration, and stringent criteria were followed
for matching MS-quantiﬁed peptides to parent proteins, it is
evident that more work is required to compare the perfor-
mance of the two systems, to see if this discrepancy extends
to other proteins with a small fold-change in expression. In
this instance, our previous observation of similar changes
in APOA4 using DiGE increases our conﬁdence in these lat-
est proteomics results, despite the inconsistency with the
ELISA.
The ELISA analysis of these three proteins was extended
from the 15 IL sample pairs also measured by MS to a furthers 5 ( 2 0 1 4 ) 10–20
13 IL and 13 NL sample pairs. Although Fig. 2 shows simi-
larities between the two groups of SL samples, particularly
compared with the NL samples, in the additional SL sample
group only SAA showed a signiﬁcant difference between pre-
labour and in-labour samples in our analyses. Examination
of the ratios of SAA and CRP levels in individual women indi-
cates that the relative increase of these proteins is not uniform
(Fig. 2B). Rather, there appear to be women with a substantial
increase in these proteins with labour, and others with little
or no change, or even a substantial decrease. Analysis of the
known characteristics of the women in these groups did not
reveal any obvious differences. Moreover, the individuals with
substantial upregulation of these two proteins form overlap-
ping, but nonidentical groups, suggesting that SAA and CRP,
although both acute phase proteins, might not be acting in the
same pathway at the time of labour.
The mechanism for the onset of labour in women remains
elusive and we can only speculate as to whether the changes
that we detected are causes or consequences of labour.
Successful parturition involves connective tissue changes
necessary for cervical ripening and dilatation, biochemical
and electrophysiological activation of myometrial smooth
muscle, metabolic changes in the uterus and placenta to
cope with episodes of hypoxia during several hours of phasic
contractions, and haemostatic responses as well as tonic con-
tractions to prevent excessive uterine bleeding post-delivery.
Other physiological changes occur in preparation for lactation
and for the extensive uterine remodelling in the puerperium.
Our data show that these complex events are reﬂected by
changes in the relative concentrations of more than 30 pro-
teins in plasma. Most of the proteins decrease with labour,
although proteins of the acute phase reaction increase. Until
we discover the physiological trigger(s) for parturition in
women, it will be difﬁcult to distinguish between primary
pathways required to establish labour and secondary path-
ways that reﬂect a general or tissue-speciﬁc response to the
progress of labour. TMT MS proteomics is a valid methodology
for identiﬁcation of such changes, if they are reﬂected in levels
of maternal plasma proteins.
This study provides a basis for further studies measuring
maternal plasma protein changes at more frequent intervals
during pregnancy and parturition and analysing differences
between spontaneous and induced labour at early stages of
the labour process.
5. Conclusion
TMT labelling with Orbitrap mass spectrometry is ideally
suited to analysis of changes in thematernal plasmaproteome
at the time of labour. The technique does not require deple-
tion of high-abundance proteins or gel separation of peptides,
and it provides quantitative and qualitative information on
hundreds of proteins per run. We have used this technique
to identify with conﬁdence 14 plasma proteins whose lev-
els change signiﬁcantly with labour at term. Further research
should address whether changes in these proteins occur prior
to labour and whether they can be used to predict the onset
of term and preterm labour.
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